Sebastian Dzierzęcki1,2, Grzegorz Turek3, Bartosz Czapski3, Katarzyna Dyttus-Cebulok2,4, Ryszard Tomasiuk5, Szymon Kaczor3, Mirosław Ząbek1,2,3. 1. Department of Neurosurgery, Postgraduate Medical Centre, Warsaw, Poland. 2. Gamma Knife Centre, Warsaw, Poland. 3. Department of Neurosurgery, Brodno Masovian Hospital, Warsaw, Poland. 4. Department of Radiation Oncology, Maria Sklodowska-Curie Institute of Oncology, Warsaw, Poland. 5. Department of Laboratory Diagnostics, Brodno Masovian Hospital, Warsaw, Poland.
Abstract
OBJECTIVE: According to the literature, gamma knife surgery (GKS) is a promising method for intracanalicular vestibular schwannoma (IVS) management, providing excellent tumor growth control rates (91%-100%) and good hearing preservation rates (41%-76%), but this evidence originates primarily from a small series of patients. The aim of this study was to present the outcomes of GKS in the largest group of patients with IVS studied to date, with particular emphasis on the long-term outcomes of treatment. METHODS: The study included 136 consecutive patients with unilateral IVS, who underwent GKS in 2011-2015. Mean age of the patients was 54 ± 12.6 years. All patients were operated on with a 192-source cobalt-60 gamma knife unit. All patients had complete follow-up documentation and the mean duration of the follow-up was 52 ± 13.8 months (6-83 months). Neurological status (facial and trigeminal nerve), hearing and instability/dizziness presence were determined prior to GKS, immediately after the procedure, and during the follow-up visits. RESULTS: Tumor growth control was obtained in 124/136 (~91.2%) patients. Hearing improvement was observed in 32/136 (23.5%) patients, and there was a distinct cluster of 9 patients (6.6%) regaining serviceable hearing after GKS, whereas in 36 patients (26.5%) was stable. Four patients developed facial nerve dysfunction, including 3 periodic hemifacial spasm and 1 partial paresis, which resolved spontaneously within 12 months of GKS. None of the operated patients showed new, debilitating neurological deficits, including trigeminal sensory disturbances or hydrocephalus. CONCLUSIONS: GKS is a highly effective treatment for IVS, associated with low morbidity and good tumor growth control.
OBJECTIVE: According to the literature, gamma knife surgery (GKS) is a promising method for intracanalicular vestibular schwannoma (IVS) management, providing excellent tumor growth control rates (91%-100%) and good hearing preservation rates (41%-76%), but this evidence originates primarily from a small series of patients. The aim of this study was to present the outcomes of GKS in the largest group of patients with IVS studied to date, with particular emphasis on the long-term outcomes of treatment. METHODS: The study included 136 consecutive patients with unilateral IVS, who underwent GKS in 2011-2015. Mean age of the patients was 54 ± 12.6 years. All patients were operated on with a 192-source cobalt-60 gamma knife unit. All patients had complete follow-up documentation and the mean duration of the follow-up was 52 ± 13.8 months (6-83 months). Neurological status (facial and trigeminal nerve), hearing and instability/dizziness presence were determined prior to GKS, immediately after the procedure, and during the follow-up visits. RESULTS:Tumor growth control was obtained in 124/136 (~91.2%) patients. Hearing improvement was observed in 32/136 (23.5%) patients, and there was a distinct cluster of 9 patients (6.6%) regaining serviceable hearing after GKS, whereas in 36 patients (26.5%) was stable. Four patients developed facial nerve dysfunction, including 3 periodic hemifacial spasm and 1 partial paresis, which resolved spontaneously within 12 months of GKS. None of the operated patients showed new, debilitating neurological deficits, including trigeminal sensory disturbances or hydrocephalus. CONCLUSIONS: GKS is a highly effective treatment for IVS, associated with low morbidity and good tumor growth control.
Authors: Maximilian Scheer; Christian Scheller; Julian Prell; Christian Mawrin; Torsten Rahne; Christian Strauss; Sebastian Simmermacher Journal: HNO Date: 2021-09-01 Impact factor: 1.330
Authors: Dilek Hacer Cesme; Alpay Alkan; Mehmet Ali Gultekin; Lutfullah Sari; Gokberk Alkan; Mehmet Hakan Seyithanoglu; Mustafa Aziz Hatiboglu Journal: Medeni Med J Date: 2021-03-26
Authors: Grzegorz Turek; Sebastian Dzierzęcki; Paweł Obierzyński; Adrian Rogala; Mateusz Ząbek; Mirosław Ząbek Journal: Wideochir Inne Tech Maloinwazyjne Date: 2022-03-31 Impact factor: 1.627